来源：财中社 1月6日，宜明昂科（01541）发布内幕消息公告，宣布与美国Axion Bio,Inc.（简称"Axion"）终止授权合 作协议，重新收回两款核心抗癌新药IMM2510（珀维拉芙普α）及IMM27M（泰泽苏拜单抗）的全球开 发与商业化权利，已收取的3500万美元首付款及里程碑付款不受影响。 两款新药均具备独特临床价值：IMM2510是靶向VEGF/PD-L1的双特异性分子，采用mAb-Trap结构，可 抑制肿瘤血管生成并激活免疫细胞，形成抗肿-瘤协同作用；IMM27M为新一代CTLA-4单抗，具有增强 的ADCC活性，能清除肿瘤微环境中的免疫抑制性调节T细胞，强化T细胞抗肿-瘤反应。宜明昂科表 示，对两款药物的治疗潜力充满信心，将加快推进其临床开发进程。 公告同时提示风险，公司无法确保IMM2510及IMM27M能成功完成研发并最终上市销售，投资者买卖 公司股份时需审慎决策。Axion为Instil Bio,Inc.全资子公司，与宜明昂科无关联关系。 据悉，双方最初于2024年8月1日达成合作，宜明昂科将IMM2510及IMM27M在大中华地区以外的全球 独家开发、商业化权利授予Axion。根据 ...

Group 1 - The core point of the news is that Haichuang Pharmaceutical has launched its self-developed Class I anti-cancer drug, Deuteroenzalutamide soft capsules, which are now available nationwide for patients with metastatic castration-resistant prostate cancer [1][2] - The drug is specifically designed for adult patients who have progressed after treatment with Abiraterone acetate and chemotherapy, and who have not previously received new androgen receptor inhibitors [1] - Prostate cancer is the second most common cancer among men globally, with 1.467 million new cases reported in 2022, and China saw 134,000 new cases in the same year, indicating a rising trend in incidence [1] Group 2 - Deuteroenzalutamide soft capsules are the first innovative drug approved in China for patients with metastatic castration-resistant prostate cancer, highlighting its clinical significance and urgent demand [1][2] - The company emphasizes its commitment to ensuring the quality and stable supply of the drug while accelerating the development of its rich pipeline of innovative therapies for global patients [2] - The drug reportedly shows superior safety compared to other endocrine therapies, significantly reducing the incidence of central nervous system adverse events and common complications in elderly patients [1]